home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

13th International Conference on Myasthenia Gravis and Related Disorders

 
  March 31, 2017  
     
 
The New York Academy of Sciences, New York
May 15-17, 2017


The treatment for myasthenia gravis (MG) — a rare, acquired autoimmune syndrome resulting in severe muscle weakness and fatigue, significant disability, and decreased life expectancy — has improved dramatically in the last several decades. While modern medical advances have reduced MG mortality rates over the last several decades, there has been an increase in reported cases especially among the aging population. The number of diagnosed MG cases is expected to rise as the aging population increases and screening techniques for MG improve. From a public health perspective it is clear that increased understanding of the etiology underlying MG is critical for enhancing diagnosis and treatment of this disease. To better translate basic research discoveries into the standard treatment regimen of MG patients, the New York Academy of Sciences, in partnership with the Myasthenia Gravis Foundation of America, will organize the 13th International Conference on Myasthenia Gravis and Related Disorders.

The conference will provide a forum for basic scientists and clinical researchers to discuss, disseminate, and highlight the advances and challenges of therapies for myasthenia gravis. The goals of this program are to: 1) provide a forum for basic, translational, and clinical researchers from academia and industry to present and discuss the most up-to-date findings in MG research; 2) explore and encourage multidisciplinary and multi-sector collaborations to enhance investigative approaches into MG and related autoimmune and neuromuscular disorders; 3) review current MG therapeutic options, ongoing clinical trials, and challenges and limitations faced in the clinic; and 4) identify knowledge gaps and future directions of research required for further breakthroughs. Ten plenary sessions will span the full spectrum of research from bench to bedside, including structure and function of the neuromuscular junction, advances in immunology, recent clinical developments related to MG, outcome measurements, clinical trial development, animal models of neuromuscular disease, MG treatment updates, congenital and Lambert-Eaton myasthenic syndromes, thymectomy, and the MGTX trial.

 
 
Organized by: The Myasthenia Gravis Foundation of America and the New York Academy of Sciences
Invited Speakers:

David Beeson, PhD, University of Oxford, United Kingdom

Michael Benatar, MD, PhD, University of Miami

Pia Bernasconi, PhD, Foundation Neurological Institute "Carlo Besta", Italy

Sonia Berrih-Aknin, DSc. INSERM, France

Ted M. Burns, MD, University of Virginia

Nadine Dragin, PhD, Institute of Myology, France

Andrew G. Engel, MD, Mayo Clinic

Amelia Evoli, MD, Catholic University, Italy

Jeffrey Guptill, MD, Duke University Medical Center

Jeannine M. Heckmann, MB ChB, PhD, University of Cape Town, South Africa

James F. Howard, Jr., MD, University of North Carolina at Chapel Hill

Maartje Huijbers, PhD, Leiden University Medical Center, The Netherlands

Isabel Illa, MD, PhD, Universitat Autonoma de Barcelona, Spain

Henry J. Kaminski, MD, George Washington University

Vijay K. Kuchroo, DVM, PhD, Harvard Institutes of Medicine

Linda L. Kusner, PhD, George Washington University

Rozen le Panse, PhD, INSERM, Franc

Claire Legay, PhD, Université Paris Descartes, Franc

Jon Martin Lindstrom, PhD, University of Pennsylvania 

Hanns Lochmuller, MD, FAAN, Newcastle University, United Kingdom

Pilar Martinez-Martinez, PhD, Maastricht University, The Netherlands

Alex Marx, MD, University of Heidelberg, Germany

Claudia Mauri, PhD, University College London, United Kingdom

Lin Mei, PhD, Augusta University

Arthur Melms, MD, Universitätsklinikum Erlangen, Germany

Rudy Mercelis, MD, PhD, Antwerp University Hospital, Belgium

Stephen D. Meriney, PhD, University of Pittsburg

Hiroyuki Murai, MD, Kyushu University, Japan

Richard J. Nowak, MD, MS, Yale University School of Medicine

Kevin C. O'Connor, PhD, Yale School of Medicine

Jacqueline Palace, MD, John Radcliffe Hospital

William Donald Phillips, PhD, University of Sydney, Australia

Jaap J. Plomp, PhD, Leiden University Medical Center, The Netherlands

Tomasz J. Prószyński, PhD, Nencki Institute of Experimental Biology, Poland

Anna Rostedt Punga, MD, PhD, Uppsala University, Sweden

Mark M. Rich, MD, PhD, Wright State University

Markus A. Ruegg, PhD, University of Basel, Switzerland

Valeria L. Salutto, MD, Medical Research Institute Alfredo Lanari, University of Buenos Aires, Argentina

Donald B. Sanders, MD, Duke University Medical Center

Clarke R. Slater, PhD, Newcastle University, United Kingdom

Jon Sussman, PhD, FRCP, Greater Manchester Neuroscience Centre, United Kingdom

Jan Verschuuren, MD, PhD, Leiden University Medical Center, The Netherlands

Angela Vincent, MSc, University of Oxford, United Kingdom

Gil I. Wolfe, MD, University of Buffalo

John S. Yi, PhD, Duke University Medical Center

Vuslat Yilmaz, PhD, Istanbul University, Turkey

 
Deadline for Abstracts: n/a
 
Registration:



By 04/03/2017After 04/03/2017
Member$100$115
Member (Student / Postdoc)$60$70
Nonmember (Academia)$125$140
Nonmember (Corporate)$150$165
Nonmember (Non-profit)$125$140
Nonmember (Student / Postdoc / Fellow)$70$85
    
    
    
    
    
    
    

E-mail: customerservice@nyas.org
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.